Introduction
results in terms of response rates and overall survival time for the combination of cytotoxic agents with the EGFR-or VEGF-targeted monoclonal antibodies, cetuximab and bevacizumab
, when used as first-or second-line treatments.
Deregulation of the raf/MAP/ERK kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway, which is involved in cell proliferation, survival and differentiation, is implicated in the development of several solid tumours, including gastric cancer [17, 18] . [20] , with dacarbazine in melanoma [21] [22] [23] , with doxorubicin in hepatocellular carcinoma [24] and with gemcitabine in pancreatic and ovarian cancer [25] [26] [27] 
The oral multikinase inhibitor sorafenib targets Raf serine/threonine kinases (raf-1, b-raf), vascular endothelial growth factor receptor (VEGFR)-1/-2/-3, platelet-derived growth factor receptor-␤ (PDGFR-␤) and Flt-3, c-kit and p38 tyrosine kinases [19]. Following interesting results obtained from experimental studies, several clinical trials have shown an antitumour activity of sorafenib used in combination with cytotoxic agents in different solid tumours. Among the various combination treatments studied, the most promising evidence of antitumour activity of the multikinase inhibitor in a phase I/II clinical setting was observed when sorafenib was combined with interferon-␣ in renal cell carcinoma

. Experimental data on gastric cancer are lacking and the few clinical studies carried out have highlighted an efficacy of sorafenib when used in combination with taxanes [28-31]. Docetaxel has been shown to be active as a single agent in patients with tumours resistant to first-line therapy or when used in combination with cisplatin and 5-FU (DCF regimen), despite
showing some toxicity [32] . The activity of the taxane in advanced gastric cancer has also been documented in neoadjuvant and perioperative regimens including radiotherapy [33, 34] . For these reasons, more tolerable docetaxel-containing regimens need to be defined, and molecular-targeted agents could be potential candidates to associate with the taxane.
In the present study we investigated the cytotoxic activity and mechanisms of action of sorafenib, used alone or in combination with docetaxel, in in vitro and in vivo gastric cancer models. Our final aim was to provide a biological rationale to use as the basis for clinical treatment planning.
Materials and methods
Cell lines
The study was performed on three cell lines (GK2, AKG, KKP) derived from human gastric adenocarcinoma (intestinal type), established and characterized in our laboratory [35, 36] 
Drug interaction analysis
TUNEL assay
Apoptotic cells were evaluated by flow cytometry [terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay] [40]. Briefly, after treatment, cells were trypsinized, fixed, exposed to the TUNEL reaction mixture, counterstained with propidium iodide and analysed by FACS.
Mitochondrial membrane potential (⌬⌿) depolarization assay
After a 20-, 40-, 60-, 120-, 240-and 360-min exposure to 10 M of sorafenib, mitochondrial membrane potential was evaluated by flow cytometry according to the previously described JC-1 method [41] . Data acquisition and analysis were performed with CELLQuest software. For each sample, 15,000 events were recorded.
Morphological analysis
After a 1-hr exposure to 0.01 M of docetaxel, cells were harvested and treated as previously described [42] . Slides (Fig. 1A) .
Cytotoxic activity of sorafenib
The activity of sorafenib in all of the cell lines after different exposure times and at different concentrations is reported in Fig. 1B by the drastic reduction in expression of their phosphorylated forms (Fig. 1C) . (Fig. 2B) . Concomitantly, strong mitochondrial membrane depolarization (⌬⌿) was observed in all four cell lines starting after only 20 min. exposure to sorafenib (Fig. 2C) . (Fig. 3A) .
Apoptosis analysis by TUNEL assay showed cell death induction in all of the cell lines ranging from 12% to 30% after a 48-hr exposure to the multikinase inhibitor (Fig. 2A). After the same exposure time, cleavage of pro-caspase-9 and -3 into their active forms was also observed, together with a reduction in the expression of the anti-apoptotic proteins, mcl-1 and p-bad
Activity of sorafenib in combination with docetaxel Different treatment schedules were used. Drug combination studies highlighted an antagonistic interaction when exposure to sorafenib preceded that of docetaxel. Simultaneous exposure to the two drugs produced only an additive interaction in GK2, AKG and KKP cells, but a synergistic effect in NCI-N87. Conversely, a synergistic interaction was obtained in all of the cell lines when docetaxel exposure preceded that of sorafenib. This synergism would appear to be highly dependent on the time interval between drug administrations. In particular, synergism was observed in all four cell lines when a 24-hr interval was used, in three cell lines using a 48-hr interval and in two cell lines for a 72-hr interval
Induction of apoptosis and caspase-3 expression were significantly higher when exposure to the taxane preceded that of sorafenib with respect to the inverse sequence (Fig. 3B) . Furthermore, after 1-hr exposure to 0.01 M of docetaxel followed by a 24-hr washout in GK2 cells, flow cytometry highlighted a subpeak on the left side of the G0/G1 peak (Fig. 4A) (Fig. 4B) . The nature of the anomalous subpopulation was investigated using a biparametric approach based on cyclin B1 detection and propidium iodide staining to search for abnormalities in mitotic exit caused by docetaxel exposure (Fig. 4C) . In GK2 cells 16 hrs after a 1-hr (Fig. 4D) . 
. Similar results were observed in the other three cell lines (data not shown). This hypopeak is not ascribable to the presence of apoptotic cells, as confirmed by the TUNEL assay
Discussion
Sorafenib is a multikinase inhibitor showing activity against the raf/MEK/ERK pathway whose inappropriate activation is a com-
mon feature in human tumours, including gastric cancer [45, 46] . Although sorafenib has proven effective in a wide variety of human cancer cell lines [47] [48] [49] [50] [51] [52] [53] , its activity has not yet been investigated in gastric cancer cells. In our work, the tyrosine kinase inhibitor showed significant cytotoxic activity in all of the cell lines when used at concentrations lower than 10 M, which corresponds to the peak plasma level reached after administration of 400 mg twice daily recommended for phase II trials [54] . Reduced MEK and ERK activation observed after sorafenib exposure supports the assumption that its antiproliferative proprieties are due mainly to the inhibition of the raf pathway, as reported for other tumour histotypes [19] . We also observed that single-agent sorafenib has important pro-apoptotic activity, triggering the mitochondrial apoptotic pathway and reducing the expression of anti-apoptotic proteins mcl-1 and p-bad. Notably, the anti-apoptotic Bcl-2 family member mcl-1, which appears to depend on ERK-mediated phosphorylation [55] [56] [57] [58] , is believed to be involved in resistance to anticancer drugs and to recurrence in gastric cancer [59, 60] .
As combining drugs with different mechanisms of action may enhance antitumour activity by overcoming drug resistance mechanisms, we tested the activity of sorafenib in combination with different conventional chemotherapeutic agents used in the treatment of advanced gastric cancer (data not shown). Among these, the most promising results were obtained from the association of sorafenib with docetaxel, while combinations with paclitaxel and gemcitabine did not produce a synergistic effect. In particular, a synergistic effect was observed in all cell lines when exposure to 
